Skip to content


Clinical Sarcoma Research


Sort by
Previous Page Page 2 of 6 Next Page
  1. Content type: Case report

    Chordomas are rare malignant tumours of the axial skeleton and skull base supposed to arise from cellular remnants of the notochord. These tumours have the potential to metastasize (30–40 %), usually in the la...

    Authors: Astrid Lipplaa, Sander Dijkstra and Hans Gelderblom

    Citation: Clinical Sarcoma Research 2016 6:19

    Published on:

  2. Content type: Research

    The role of age as a prognostic factor has been examined in single institutional studies and in larger data sets from the SEER database, showing a survival advantage for younger versus adult patients with syno...

    Authors: Bernadette Brennan, Charles Stiller, Robert Grimer, Nicola Dennis, John Broggio and Matthew Francis

    Citation: Clinical Sarcoma Research 2016 6:18

    Published on:

  3. Content type: Research

    Previous studies on high grade sarcomas using mass spectrometry imaging showed proteasome activator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. PSME1 is invol...

    Authors: Sha Lou, Arjen H. G. Cleven, Benjamin Balluff, Marieke de Graaff, Marie Kostine, Inge Briaire-de Bruijn, Liam A. McDonnell and Judith V. M. G. Bovée

    Citation: Clinical Sarcoma Research 2016 6:17

    Published on:

  4. Content type: Review

    Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosum...

    Authors: Czar Louie Gaston, Robert J. Grimer, Michael Parry, Silvia Stacchiotti, Angelo Paolo Dei Tos, Hans Gelderblom, Stefano Ferrari, Giacomo G. Baldi, Robin L. Jones, Sant Chawla, Paolo Casali, Axel LeCesne, Jean-Yves Blay, Sander P. D. Dijkstra, David M. Thomas and Piotr Rutkowski

    Citation: Clinical Sarcoma Research 2016 6:15

    Published on:

  5. Content type: Case Report

    Solitary fibrous tumour (SFT) is a rare soft tissue sarcoma with a low metastatic potential. A higher metastatic rate is observed in the high-grade/dedifferentiated variant. The most common expected site of di...

    Authors: Vittoria Colia, Salvatore Provenzano, Carlo Morosi, Paola Collini, Salvatore Lorenzo Renne, Paolo G. Dagrada, Claudia Sangalli, Angelo Paolo Dei Tos, Andrea Marrari, Paolo G. Casali and Silvia Stacchiotti

    Citation: Clinical Sarcoma Research 2016 6:16

    Published on:

  6. Content type: Research

    A chronic inflammatory cell infiltrate is commonly seen in response to primary malignant tumours of bone. This is known to contain tumour-associated macrophages (TAMs) and lymphocytes; dendritic cells (DCs) an...

    Authors: Y. Inagaki, E. Hookway, K. A. Williams, A. B. Hassan, U. Oppermann, Y. Tanaka, E. Soilleux and N. A. Athanasou

    Citation: Clinical Sarcoma Research 2016 6:13

    Published on:

  7. Content type: Research

    Advances in treatment of sarcoma patients has prolonged survival but has led to increased disease- or treatment-related complications resulting in greater number of admissions to the intensive care unit (ICU)....

    Authors: Rohan Gupta, Neda Heshami, Chouhan Jay, Naveen Ramesh, Juhee Song, Xiudong Lei, Erfe Jean Rose, Kristen Carter, Dejka M. Araujo, Robert S. Benjamin, Shreyaskumar Patel, Joseph L. Nates and Vinod Ravi

    Citation: Clinical Sarcoma Research 2016 6:12

    Published on:

  8. Content type: Research

    There is a paucity of data on the current management of patients with advanced soft tissue sarcoma (STS) in the Australian health care setting. This study utilised the Australian sarcoma database to evaluate t...

    Authors: Susie Bae, Philip Crowe, Raghu Gowda, Warren Joubert, Richard Carey-Smith, Paul Stalley and Jayesh Desai

    Citation: Clinical Sarcoma Research 2016 6:11

    Published on:

  9. Content type: Research

    Most GISTs have mutations in KIT or PDGFRA. Patients with advanced GIST with KIT exon 9, PDGFRA mutation or WT for KIT and PDGFRA have a worse progression-free survival (PFS) compared to patients with KIT exon...

    Authors: Joan Maurel, Antonio López-Pousa, Silvia Calabuig, Silvia Bagué, Xavier Garcia del Muro, Xavier Sanjuan, Jordi Rubió-Casadevall, Miriam Cuatrecasas, Javier Martinez-Trufero, Carlos Horndler, Joaquin Fra, Claudia Valverde, Andrés Redondo, Andrés Poveda, Isabel Sevilla, Nuria Lainez…

    Citation: Clinical Sarcoma Research 2016 6:10

    Published on:

  10. Content type: Review

    Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the grow...

    Authors: Kieuhoa T. Vo, Katherine K. Matthay and Steven G. DuBois

    Citation: Clinical Sarcoma Research 2016 6:9

    Published on:

  11. Content type: Research

    Angiosarcoma is a rare subgroup of soft tissue sarcomas associated with poor prognosis, but paclitaxel has been shown to be active in pretreated metastatic disease. We investigated the efficacy and safety of w...

    Authors: Seonggyu Byeon, Haa-Na Song, Hee Kyung Kim, Jun Soo Ham, Su Jin Lee, Jeeyun Lee and Se Hoon Park

    Citation: Clinical Sarcoma Research 2016 6:8

    Published on:

  12. Content type: Review

    This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommend...

    Authors: Craig Gerrand, Nick Athanasou, Bernadette Brennan, Robert Grimer, Ian Judson, Bruce Morland, David Peake, Beatrice Seddon and Jeremy Whelan

    Citation: Clinical Sarcoma Research 2016 6:7

    Published on:

  13. Content type: Research

    Zoledronic acid (ZA) is a third-generation bisphosphonate in widespread clinical use to reduce pain and skeletal events in patients from a variety of malignancies with bone metastases. Pre-clinical studies ind...

    Authors: Robert M. Conry, Michael G. Rodriguez and Joseph G. Pressey

    Citation: Clinical Sarcoma Research 2016 6:6

    Published on:

  14. Content type: Case Report

    Kaposi sarcoma is a neoplastic vascular disorder. It usually present on the skin of the upper and lower extremities, rarely in the mucosa of the head and neck. The most common sites reported are within the ora...

    Authors: Karima Mouden, Mouna Khmou, Saida Loughmari, Afaf Semmar, Hanan El Kacemi, Basma El Khannoussi, Tayeb Kebdani, Sanaa Elmajjaoui and Noureddine Benjaafar

    Citation: Clinical Sarcoma Research 2016 6:4

    Published on:

  15. Content type: Meeting Report

    This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children’s Cancer Research Institute in Vienna, ...

    Authors: Leo Kager, Jeremy Whelan, Uta Dirksen, Bass Hassan, Jakob Anninga, Lindsey Bennister, Judith V. M. G. Bovée, Bernadette Brennan, Javier M. Broto, Laurence Brugières, Anne-Marie Cleton-Jansen, Christopher Copland, Aurélie Dutour, Franca Fagioli, Stefano Ferrari, Marta Fiocco…

    Citation: Clinical Sarcoma Research 2016 6:3

    Published on:

  16. Content type: Case Report

    Abdominal leiomyosarcoma arising from the mesentery is a rare malignancy. It is an aggressive entity with an overall 5 year survival rate between 20 and 30 %. Surgical resection is the cornerstone of primary t...

    Authors: Mercy Varghese, Oyvind Bruland, Anne Marit Wiedswang, Ingvild Lobmaier, Bård Røsok, Robert S. Benjamin and Kirsten Sundby Hall

    Citation: Clinical Sarcoma Research 2016 6:2

    Published on:

  17. Content type: Research

    Wide local excision with or without radiation therapy (RT) and chemotherapy is widely accepted as appropriate management for soft tissue sarcomas (STS) of the extremity. Although survival and local control rat...

    Authors: Michael Ziegele, David M. King and Manpreet Bedi

    Citation: Clinical Sarcoma Research 2016 6:1

    Published on:

  18. Content type: Case Report

    Desmoid tumors are rare benign monoclonal fibroblastic tumors. Their aggressiveness is local with no potential for metastasis or dedifferentiation. Here we report on a 61-year-old patient who presented a local...

    Authors: François Bertucci, Marjorie Faure, Maria-Rosa Ghigna, Bruno Chetaille, Jérôme Guiramand, Laurence Moureau-Zabotto, Anthony Sarran and Delphine Perrot

    Citation: Clinical Sarcoma Research 2015 5:25

    Published on:

  19. Content type: Case Report

    Rhabdomyosarcoma (RMS), a malignant tumour of mesenchymal origin which can occur at various sites in the body, is one of the most common soft tissue sarcomas in both children and adolescents, but is rare in ad...

    Authors: Panagiotis Karagiannis, Nina Guth, Gabriela B. Thoennissen, Christina Bern, Jan Sperveslage, Ilske Oschlies, Carsten Bokemeyer, Wolfram Klapper, Eva Wardelmann and Nils H. Thoennissen

    Citation: Clinical Sarcoma Research 2015 5:24

    Published on:

  20. Content type: Research

    High-grade foci (grade 3 according to Broder’s grading system) are sometimes detected in low-grade (grade 1 and 2) central osteosarcoma. The aim of this study was to retrospectively evaluate the clinical outco...

    Authors: Alberto Righi, Anna Paioli, Angelo Paolo Dei Tos, Marco Gambarotti, Emanuela Palmerini, Manuela Cesari, Emanuela Marchesi, Davide Maria Donati, Piero Picci and Stefano Ferrari

    Citation: Clinical Sarcoma Research 2015 5:23

    Published on:

  21. Content type: Case Report

    Pseudomyogenic hemangioendothelioma (PMH) is a recently described, indolent vascular tumor that usually presents in the distal extremities. PMH typically has a multi-focal presentation and can involve several ...

    Authors: Jason Joseph, Wei-lien Wang, Madhavi Patnana, Naveen Ramesh, Robert Benjamin, Shreyaskumar Patel and Vinod Ravi

    Citation: Clinical Sarcoma Research 2015 5:22

    Published on:

  22. Content type: Case Report

    Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in either KIT or PDGFRA. Importantly, different mutations within these two genes can lead to very different levels of sensitivit...

    Authors: Andrew S. Brohl, Elizabeth G. Demicco, Karen Mourtzikos and Robert G. Maki

    Citation: Clinical Sarcoma Research 2015 5:21

    Published on:

Previous Page Page 2 of 6 Next Page